Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

By News Health
7 hours Ago

(MedPage Today) — The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results…

Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/119027

Author :

Publish date : 2025-12-15 21:28:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Pyloroplasty With Electric Stimulation Treats Gastroparesis

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms